Product Images Cyclobenzaprine Hydrochloride

This text presents the percentages of side effects experienced by patients taking cyclobenzaprine HCI tablets in both 5mg and 10mg doses, as well as a placebo group. The side effects listed are drowsiness, dry mouth, fatigue, and headache. For the 5mg group, 29% experienced drowsiness, 21% experienced dry mouth, 6% experienced fatigue, and 5% experienced a headache. For the 10mg group, 38% experienced drowsiness, 32% experienced dry mouth, 6% experienced fatigue, and 5% experienced a headache. The placebo group experienced these side effects at a much lower percentage, ranging from 3% to 10%.*

This text appears to be a report on the results of clinical studies and a surveillance program involving Cyclobenzaprine HCI Tablets. The studies found that 39% of patients experienced drowsiness as a side effect, while 2% experienced dry mouth and 1% experienced dizziness. The surveillance program found higher rates of side effects, with 16% of patients experiencing drowsiness, 7% experiencing dry mouth, and 3% experiencing dizziness. Overall, the text suggests that Cyclobenzaprine HCI Tablets may have significant side effects, and caution should be exercised when prescribing them.*

This is a description of a medication package containing 7 tablets of Cyclobenzaprine HCL 5mg, with an expiration date of 06/21. The usual adult dosage is included in the package insert. The lot number is 902657X1 and it should be stored at room temperature. The manufacturer is Mig InvaGen Pharmaceuticals Inc, with a distribution by Redpharm Drug in Eden Prairie, MN. The NDC code is 67296-1728-7.*